Andrew Hill Investment Advisors Inc. Has $212,000 Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Andrew Hill Investment Advisors Inc. cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 80.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 512 shares of the company’s stock after selling 2,155 shares during the quarter. Andrew Hill Investment Advisors Inc.’s holdings in IDEXX Laboratories were worth $212,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in IDXX. Insight Wealth Strategies LLC grew its holdings in shares of IDEXX Laboratories by 230.5% in the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock valued at $4,174,000 after acquiring an additional 7,041 shares in the last quarter. Geode Capital Management LLC raised its stake in IDEXX Laboratories by 1.8% during the third quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company’s stock valued at $1,138,732,000 after buying an additional 40,349 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of IDEXX Laboratories during the third quarter valued at approximately $1,263,000. Sax Wealth Advisors LLC grew its holdings in IDEXX Laboratories by 76.3% during the fourth quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company’s stock valued at $590,000 after purchasing an additional 617 shares during the period. Finally, Hantz Financial Services Inc. lifted its holdings in IDEXX Laboratories by 11.5% in the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company’s stock worth $3,199,000 after purchasing an additional 800 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 10.0 %

NASDAQ:IDXX opened at $397.10 on Thursday. The firm has a market capitalization of $32.18 billion, a price-to-earnings ratio of 37.22, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The business has a fifty day moving average price of $431.26 and a 200-day moving average price of $435.73. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $548.88.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Barclays raised their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Morgan Stanley lowered their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, April 4th. Bank of America increased their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Finally, Piper Sandler increased their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $533.75.

Insider Buying and Selling

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.